Systemic protein therapy for recessive dystrophic epidermolysis bullosa: how far are we from clinical translation?

Abstract

In this issue, Woodley et al. report restoration of anchoring fibril formation and dermal-epidermal adherence in a murine model of recessive dystrophic epidermolysis bullosa (RDEB) by intravenous injection of recombinant human type VII collagen. This work follows a previous report by the same group of the surprising capability of intradermally injected type VII collagen protein to reverse RDEB, and it opens new therapeutic avenues.

• Authors: Alain Hovnanian
• Journal: The Journal of investigative dermatology (J Invest Dermatol) Vol. 133 Issue 7 Pg. 1719-21 (Jul 2013) ISSN: 1523-1747 [Electronic] United States
• PMID: 23760051 (Publication Type: Journal Article, Comment)

Chemical References

• Collagen Type VII

Topics

• Animals
• Collagen Type VII (pharmacology, therapeutic use)
• Epidermolysis Bullosa Dystrophica (drug therapy, pathology)
• Humans
• Skin (drug effects)
• Wounds and Injuries (drug therapy)